Holen Sie sich die Stockscreener-App
1.96
0.65%
0.0127
Schlusskurs vom Vortag:
$1.9473
Offen:
$1.93
24-Stunden-Volumen:
2,730
Relative Volume:
0.08
Marktkapitalisierung:
$6.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.72M
KGV:
-0.7426
EPS:
-2.6394
Netto-Cashflow:
$-6.25M
1W Leistung:
+7.13%
1M Leistung:
+4.26%
6M Leistung:
-58.74%
1J Leistung:
-61.72%
1-Tages-Spanne:
$1.9001
$2.0163
1-Wochen-Bereich:
$1.83
$2.06
52-Wochen-Spanne:
$1.55
$5.99
Edesa Biotech Inc Stock (EDSA) Company Profile
Firmenname
Edesa Biotech Inc
Sektor
Branche
Telefon
(905) 475-1234
Adresse
100 SPY COURT, MARKHAM, ON
Vergleichen Sie EDSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
1.93 | 6.69M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.76 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
708.82 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
666.15 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.69 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.99 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edesa Biotech Inc Aktie (EDSA) Neueste Nachrichten
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo - Research Tree
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo… - Yahoo Finance
Edesa Biotech Announces $4.36 million Registered Direct Offering - ACCESS Newswire
Edesa Biotech, Inc. (NASDAQ:EDSA) Short Interest Update - Defense World
EDSA Stock Touches 52-Week Low at $1.69 Amid Market Challenges - Investing.com
Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar - Simply Wall St
Edesa Biotech Reports Fiscal Year 2024 Results - The Manila Times
Edesa Biotech Inc. (EDSA) reports earnings - Quartz
Edesa Biotech Slashes Operating Costs 20%, Secures Government Backing for ARDS Drug Development - StockTitan
Edesa Biotech stock hits 52-week low at $2.02 amid challenges - Investing.com Nigeria
Edesa Biotech stock hits 52-week low at $2.02 amid challenges By Investing.com - Investing.com South Africa
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 192.2% - Defense World
EDSA stock touches 52-week low at $2.08 amid market challenges - Investing.com India
EDSA stock touches 52-week low at $2.08 amid market challenges By Investing.com - Investing.com South Africa
Edesa Biotech (NASDAQ:EDSA) Shares Up 4.7% – Here’s Why - Defense World
EDSA stock touches 52-week low at $2.27 amid market challenges - Investing.com Canada
Edesa Leaps as CEO Boosts Holdings - Baystreet.ca
Edesa Biotech CEO invests $5 million in company By Investing.com - Investing.com India
Edesa Biotech’s Founder Makes Strategic Investment in the Company - GlobeNewswire
Edesa Biotech to Present at Global Conferences - Nasdaq
Edesa Biotech Announces Upcoming Conference Schedule - GlobeNewswire
Edesa Biotech Partners with Wainwright for Share Sales - TipRanks
Edesa Biotech (EDSA) Price Target Increased by 528.00% to 53.38 - MSN
Why Is Infectious Disease Player Edesa Biotech Stock Soaring Today? - MSN
Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - GlobeNewswire Inc.
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
1 Dividend Stock to Invest in the Domestic Steel Market Now - The Globe and Mail
Celsius Holdings Inc (CELH-Q) QuotePress Release - The Globe and Mail
Mackenzie Investments Announces Results of Special Meetings on Mutual Fund and ETF Mergers - Yahoo Canada Finance
ECB interest rate cut likely as Eurozone economy weaker than expected - Yahoo Finance UK
Veradigm Named as the Top Vendor for End-to-End Revenue Cycle Management Solutions - Yahoo Finance UK
Santander starts $1.7 billion share buyback programme - Yahoo Finance UK
FY2024 Earnings Estimate for Edesa Biotech, Inc. (NASDAQ:EDSA) Issued By HC Wainwright - Defense World
H.C. Wainwright bullish on Edesa Biotech stock amid BARDA study support - Investing.com
Edesa Biotech’s (EDSA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
500: Something went wrong - Investing.com UK
EDSA: EB05 Selected for BARDA-Funded Study in ARDS… - Yahoo Finance
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Stock Price Down 2% - Defense World
Edesa Biotech Inc expected to post a loss of 58 cents a shareEarnings Preview - XM
Ethiopian Airlines posts 14% jump in full-year revenue - Yahoo Finance UK
Alexis Shamess | Corporate/Commercial Lawyer in Toronto | People - Fasken
MoneySmart’s June Lucky Draw 2024 - Yahoo Finance
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential - Yahoo Finance UK
Homebuilder Vistry boosts output target as cost inflation softens - Yahoo Finance UK
German environmental authorities approve Tesla site expansion - Yahoo Finance UK
Cipher Pharmaceuticals - The Pharma Letter
Edesa’s Paridiprubart Selected For U.S.-Funded Platform Trial In General ARDS - Contract Pharma
French jet engine maker Safran gets Italy's clearance to buy Microtecnica - Yahoo Finance UK
EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo - Yahoo Finance
Finanzdaten der Edesa Biotech Inc-Aktie (EDSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
2.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):